Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.37 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606849 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL30843231 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL4653458 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL12899847 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL29776749 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL5971391 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL13177330 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL5707581 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL17285835 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL17285836 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112794858-B | Preparation method of compound with 3,4-trans-3, 6-anhydro-hexofuranose structure | 中国药科大学 | 2021-06-25 | — | — | CN | disclosed |
| CN-112794858-A | Preparation method of compound with 3,4-trans-3, 6-anhydro-hexofuranose structure | 中国药科大学 | 2021-05-14 | — | — | CN | disclosed |
| US-20060229275-A1 | Production method of 2-deoxy-L-ribofuranosyl chloride compound | AJINOMOTO CO. INC (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1705181-A2 | Production method of 2-deoxy-L-ribofuranosyl chloride compound | AJINOMOTO CO., INC. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229275-A1 | Production method of 2-deoxy-L-ribofuranosyl chloride compound | DCTD, DERA, HDHD5 | PYGB 3282/4885PYGL 2630/4885PYGM 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.